Rheumatic immune adverse effects posing challenges for oncology patients

There are still more questions than answers about rheumatic immune-related adverse events (irAEs) associated with anti-programmed death 1 (PD-1) cancer therapies. However an Australian case series of 36 cancer patients with either rheumatic disease preceding their immunotherapy or who developed de novo rheumatic irAEs after treatment has shed some more light on their presentation, management ...

Already a member?

Login to keep reading.

© 2021 the limbic